Rank power of metrics used to assess QTc interval prolongation by clinical trial simulation

Journal of Clinical Pharmacology

Volumn 40, Issue 5, 2000, Pages 468-474

  Bonate, P L ^a  

^a IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AREA UNDER THE CURVE; ARTICLE; COVARIANCE; DATA ANALYSIS; ELECTROCARDIOGRAPHY; HEART ARRHYTHMIA; HEART REPOLARIZATION; LONG QT SYNDROME; QT INTERVAL; RISK ASSESSMENT; SIMULATION; SYSTEM ANALYSIS;

EID: 0033663359     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700022009233     Document Type: Article

References (14)

1. The antipsychotic agent is a high affinity antagonist of the human cardiac potassium channel HERG
2. Comparative effects of loratadine and terfenadine on cardiac K+ channels
3. QTc prolongation measured by standard 12-lead ECG is an independent risk factor for sudden death due to cardiac arrest
4. An analysis of time-relations of electrocardiograms
5. Die systolendauer im elektrokardiogramm bei normalen menschen und bei herzkranken
6. Assessment of QTc prolongation for noncardiac drugs from a drug development perspective
7. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia
8. Covariation and reliability of ECG parameters during 24 hour monitoring
9. Further comparative analyses of pretest-posttest research designs
10. Origins of baseline variance and the law of initial values
11. Regression toward the mean and the study of change
12. How much of the placebo 'effect' is really statistical regression?